MedicarePartD.guide

A non-government resource built from CMS public data

2026 Blue Rx PDP Complete (PDP) formulary (drug list)

Contract S5593, plan 003 · West Virginia · 3,788 drugs on file · formulary ID 00026017. Each drug links to its cost in every CMS PDP Region 06 plan.

Hide drugs on tiers

15 drugs starting with Y.

Drug nameTier30-day preferred pharmacy90-day mail orderUsage management
YARGESA 100 mg CapsuleMiglustat5Specialty Tier25%N/A
  • PA
  • QL 93 per 31 days
YESINTEK 45 mg/.5mL Injection, SolutionUstekinumab3Preferred Brand25%25%
  • PA
  • QL 0.5 per 84 days
YESINTEK 45 mg/.5mL Injection, SolutionUstekinumab3Preferred Brand25%25%
  • PA
  • QL 0.5 per 84 days
YESINTEK 90 mg/mL Injection, SolutionUstekinumab5Specialty Tier25%N/A
  • PA
  • QL 1 per 56 days
YF-VAX 4.74 [PFU]/.5mL Injection, Powder, Lyophilized, For SuspensionYellow Fever Virus Strain 17D-204 Live Antigen3Preferred Brand25%25%None
YONSA 125 mg TabletAbiraterone Acetate5Specialty Tier25%N/A
  • PA
  • QL 124 per 31 days
YORVIPATH 168 ug/.56mL Injection, SolutionPalopegteriparatide5Specialty Tier25%N/A
  • PA
  • QL 1.12 per 28 days
YORVIPATH 294 ug/.98mL Injection, SolutionPalopegteriparatide5Specialty Tier25%N/A
  • PA
  • QL 1.96 per 28 days
YORVIPATH 420 ug/1.4mL Injection, SolutionPalopegteriparatide5Specialty Tier25%N/A
  • PA
  • QL 2.8 per 28 days
YUFLYMA KitAdalimumab-Aaty5Specialty Tier25%N/A
  • PA
  • QL 2 per 28 days
YUFLYMA KitAdalimumab-Aaty5Specialty Tier25%N/A
  • PA
  • QL 6 per 365 days
YUFLYMA KitAdalimumab-Aaty5Specialty Tier25%N/A
  • PA
  • QL 2 per 28 days
YUFLYMA KitAdalimumab-Aaty5Specialty Tier25%N/A
  • PA
  • QL 2 per 28 days
YUPELRI 175 ug/3mL SolutionRevefenacin5Specialty Tier25%N/A
  • PA
YUVAFEM 10 ug TabletEstradiol4Non-Preferred Drug25%25%None

PA = prior authorization, ST = step therapy, QL = quantity limit. Costs are the plan’s initial-coverage cost-sharing from the CMS 2026 formulary files; a drug not listed here is not on this plan’s formulary, though a formulary exception may still be possible.